Home › Therapeutic areas › Oncology › Pancreatic Cancer
Pancreatic Cancer (27 companies)
Companies with an active program in Pancreatic Cancer.
| Ticker | Company | Therapeutic areas | Programs | Lead stage | Mkt cap | Programs |
|---|---|---|---|---|---|---|
| ACRV | Acrivon Therapeutics | GI/HepatologyOncology Rare | 1 | Phase 2 | $61.4M | 9 |
| ACTU | Actuate Therapeutics | Oncology | 1 | Phase 2 | $15.2M | 4 |
| ALLO | Allogene Therapeutics | ImmunologyOncology Rare | 1 | Phase 2 | $256M | 10 |
| DRTS | Alpha Tau Medical | Oncology | 1 | Phase 2 | $1.12B | 6 |
| RCUS | Arcus Biosciences | DermatologyImmunology+1 | 1 | Phase 3 | $2.36B | 8 |
| BCYC | Bicycle Therapeutics | Oncology | 1 | Phase 2 | $224M | 4 |
| BBOT | BridgeBio Oncology Therapeutics | Oncology | 2 | Phase 1 | $156M | 6 |
| CLRB | Cellectar Biosciences | Oncology | 1 | Phase 2 | $9.2M | 7 |
| CTMX | CytomX Therapeutics | Oncology | 1 | Phase 1 | $423M | 7 |
| EIKN | Eikon Therapeutics | Oncology | 2 | Phase 2 | $279M | 13 |
| ELTX | Elicio Therapeutics | Oncology | 2 | Phase 2 | $40.5M | 6 |
| ERAS | Erasca | Oncology | 1 | Phase 1 | $4.87B | 5 |
| IDYA | IDEAYA Biosciences | Oncology | 1 | NDA Submitted | $2.65B | 15 |
| IMRX | Immuneering | Oncology | 1 | Phase 3 | $224M | 5 |
| IBRX | ImmunityBio | Infectious DiseaseOncology | 2 | Approved | $6.66B | 17 |
| KURA | Kura Oncology | MetabolicOncology | 1 | Approved | $688M | 13 |
| LEGN | Legend Biotech | Oncology Rare | 1 | Approved | $3.12B | 17 |
| MRKR | Marker Therapeutics | Oncology | 1 | Phase 1 | $14.0M | 5 |
| MBRX | Moleculin Biotech | Oncology | 1 | Phase 2 | $7.3M | 9 |
| NBP | NovaBridge Biosciences | OncologyOphthalmology | 1 | Phase 2 | $95.4M | 7 |
| ONCY | Oncolytics Biotech | Oncology | 1 | Phase 2 | $51.7M | 4 |
| PMVP | PMV Pharmaceuticals | Oncology | 1 | Phase 2 | $92.2M | 7 |
| RVMD | Revolution Medicines | Oncology | 2 | Approved | $35.2B | 11 |
| SLS | SELLAS Life Sciences Group | Oncology | 1 | Phase 3 | $3.90B | 9 |
| TNGX | Tango Therapeutics | Oncology | 1 | Phase 1 | $3.75B | 5 |
| VSTM | Verastem | Oncology | 2 | Approved | $934M | 5 |
| XNCR | Xencor | ImmunologyNeurology+1 Rare | 1 | Approved | $2.59B | 28 |
No companies match.